The present study revealed that in HER2-positive breast cancer patients receiving neoadjuvant dual anti-HER2 therapy, the GDF-15 level was greater in patients who experienced cardiotoxicity than in those who did not. This evidence concerns the gene GDF15 and breast carcinoma.